Vertex Shares Plunge After Q2 Results; Guidance Short of Street Expectations
Vertex Pharmaceuticals' stock dropped sharply after a post-close Q2 2026 report that, while modestly beating consensus on earnings and revenue, set a Q3 revenue range whose midpoint sits below Wall Street estimates and revealed a steep contraction in free cash flow as capital spending rose. The decline reflects company-specific concerns rather than…